The Atypical HUS Foundation

Send Your Submission to the PBAC in Australia to Help Our aHUS Friends on Dialysis

Here’s a new way you can help our friends from Australia.  In March 2016 there will be a meeting by the PBAC to determine if Soliris should be provided to aHUS patients who are on dialysis.  You can send a personal submission to the PBAC to show your support of our Australian friends.  We only have until Feb 10, 2016 to send them so please hurry and ask your family and friends to help.  I listed my answers to some of the questions that you may have trouble thinking of answers to, so feel free to copy my answers.  We need to send as many of these as we can!

Here is the link to fill out the submission:

http://www.health.gov.au/internet/main/publishing.nsf/Content/PBAC_...

 

Here is the link to the agenda of the meeting:

http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/...

***********************************************************

Medicine to which this submission relates :  

Soliris (Eculizumab)

Date of PBAC meeting: 

March 2016

Submitted by (individual, collective group, health professional): 

Jeff Schmidt


Please include any declarations you wish to make regarding the PBAC submission upon which you are commenting. If you have no declarations to make, please respond “nil”:  
 

aHUS patients who are on dialysis are in need of a transplant because they did not have access to Soliris when they got sick and they therefore lost their kidney function.  These patients are generally not considered for a transplant because of the high risk of the aHUS recurring and therefore causing the transplanted kidney to also fail.   The body produces antibodies after receiving someone else’s organ; it is these antibodies that trigger the immune system to become active, which is what triggers an aHUS response.  The newly donated kidney is vulnerable so it is imperative that Soliris is available for patients pre and post transplant.  Due to lack of available donated organs in Australia I can not comprehend why you would put a gift such as a donated organ at risk.


Consumer input: Please indicate whether you are a person with this medical condition, a friend or family member, a prescriber, a representative of an organisation or other interested person:  

I am a family member.


What comments would you like the PBAC to take into account when it considers this submission? You may comment on any aspect of the drug, vaccine or medicinal product in question. The following points may be useful for guidance: 
 

For years, Belgium has had the same policy as Australia where as those on dialysis were not considered for access to Soliris. But on December 23, 2015, Maggie De Block, Minister of Social Affairs and Public Health, announced that she had reached an agreement with Alexion Pharmaceuticals. And from this agreement, the orphan drug Soliris will be available immediately to all Belgian patients with ESRD caused by atypical hemolytic uremic syndrome (aHUS). These patients will therefore be placed on the waiting list for a kidney transplant. It was agreed that access to Soliris should reduce the risk of rejection of the donated kidney. We applaud Ms. De Block for her decision to save the lives of those patients on dialysis.  And we ask you to do the same.


How did you learn about this consumer submission process to be able to submit your comments today? Are there any other comments you would like to make about the process for submitting consumer input to the PBAC?  

I learned about this from aSPGA (AHUS Patient Support Group Australia).

Views: 618

Comment

You need to be a member of The Atypical HUS Foundation to add comments!

Join The Atypical HUS Foundation

Badge

Loading…

© 2017   Created by Deborah Lewis.   Powered by

Badges  |  Report an Issue  |  Terms of Service